UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) January 4, 2007
(December 26, 2006)
REPLIDYNE, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
1450 Infinite Drive,
Louisville, Colorado
(Address of principal executive offices)
|
|
000-52082
(Commission File Number)
|
|
84-1568247
(I.R.S. Employer
Identification No.)
80026
(Zip Code) |
303-996-5500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
INFORMATION TO BE INCLUDED IN THE REPORT
Section 7 — Regulation FD
Item 7.01 Regulation FD Disclosure.
On December 26, 2006, Replidyne, Inc. (the ‘Company”) issued a press release announcing that the
Company is stopping the current phase III clinical trial comparing faropenem medoxomil (faropenem)
to placebo and Ketek (telithromycin) in patients being treated for acute exacerbation of chronic
bronchitis (AECB) to consider the ongoing inclusion of the Ketek arm in the study. A copy of the
press release is furnished as Exhibit 99.1 to this Form 8-K.
In accordance with General Instruction B.2. of Form 8-K, the information presented under this Item
7.01 and attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific
reference in such a filing.
Section 9 — Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
| |
99.1 |
|
Press Release, dated December 26, 2006, Entitled “Faropenem Phase III
Clinical Trial Stopped to Consider Exclusion of Ketek Comparator.” |